Pharmacokinetics of Cyadox and Its Major Metabolites in Swine After Intravenous and Oral Administration

Pharmacokinetics of cyadox （CYX） and its major metabolites in healthy swine was investigated in this paper. 1,4- Bisdesoxycyadox （BDCYX）, cyadox-1-monoxide （CYX-1-O） and quinoxaline-2-carboxylic acid （QCA）, three main metabolites of cyadox, were synthesized by College of Science, China Agricultural University. Cyadox （CYX） was administered to 8 healthy cross-bread swine intravenously （i.v.） and orally （p.o.） at a dosage of 1 mg kg^-1 body weight and 40 mg kg-1 body weight respectively in a randomized crossover design test with 2-wk washout period. A sensitive high-performance liquid chromatography-tandem mass spectrometry （LC-ESI-MS/MS） method was developed for the determination of cyadox and its major metabolites in plasma. CYX and its major metabolites BDCYX, and CYX-1-O can be detected after intravenous administration of cyadox while CYX and its metabolites BDCYX, CYX-1-O and QCA can be detected after oral administration of CYX. Plasma concentration vs. time profiles of CYX and its major metabolites were analyzed by non-compartmental pharmacokinetic method. Following i.v. administration, the areas under the plasma concentration-time curve （AUC0-∞） were （0.38±0.03） lag mL-I h （CYX）, （0.018±0.002） lag mL-1 h （BDCYX） and （0.17±0.02） lag mL^-1 h （CYX- 1-O）, respectively. The terminal elimination half-lives （t1/2kz） were determined to be （0.93±0.07） h （CYX）, （1.45±0.04） h （BDCYX）, and （0.92±0.04） h （CYX-1-O）, respectively. Steady-state distribution volume （Vss） of （2.14±0.11） L kg^-1 and total body clearance （CL） of （2.84±0.19） L h^-1 kg^-1 were determined for CYX after i.v. dosing. The bioavailability （F） of CYX was 2.85% for oral administration. After single i.v. administration, peak plasma concentrations （Cmax） of （1.08±0.06） lag mL^-1 （CYX）, （0.0068~ 0.0004） lag mL-1 （BDCYX） and （0.25~0.03） gg mL-~ （CYX-I-O） were observed at Tmax of 0.033 h （CYX）, 1 h （BDCYX） and 0.033 h （CYX-1-O）, respectively. The main pharmacokinetic parameters after p.o. administration were as follows： AUC0.= were （0.42~0.04） lag mL^-1 h （CYX）, （1.38±0.14） μg mL-1 h （BDCYX）, （0.59±0.02） lag mL-1 h （CYX-1-O） and （1.48＋0.09） lag mL-＇ h （QCA）, respectively, t1/2λz were （4.77±0.33） h （CYX）, （5.77±0.56） h （BDCYX）, （4.12＋0.28） h （CYX-1-O）, and （8.51＋0.39） h （QCA）, respectively. After p.o. administration, CmaxS of （0.033±0.002） μg mL^-1 （CYX）, （0.22±0.03） mg mL^-1 （BDCYX）, （0.089±0.005） μg mL^-1 （CYX-1-O）, and （0.17± 0.01） mg mL^-1 （QCA） were observed at Tmax of（7.38±0.33） h （CYX）, （7.25±0.31） h （BDCYX）, （7.38±0.33） h （CYX-1-O）, and （7.25±0.31） h （QCA）, respectively. The results showed that CYX was slowly absorbed after oral administration and most of CYX was transformed to its metabolites in swine. The area under plasma concentration-time curve （AUC0-∞）of metabolites were higher than that of CYX after p.o. administration, and the elimination half-lives （t1/2λz） of QCA were longer than those of CYX, CYX-1-O, and BDCYX after oral administration.

在役刚架拱桥病害分析及加固设计研究

基于某在役刚架拱桥次拱腿断裂及横向连杆脱落等病害问题,通过建立多种工况有限元分析模型,对比分析了不同工况下的内力,进一步了解病害产生原因,提出了对应的加固措施,并开展了桥梁荷载试验。结果表明:该桥病害中破损及缺失构件并非主要受力构件,可以采用粘贴钢板的加固方案对桥梁病害出现的位置及主要受力部分进行加固,以此满足公路Ⅱ级荷载标准。

山区高速预制装配桥梁关键技术研究及应用

从传统现场浇筑施工方法缺点出发,针对山区高速存在运榆困难、地势起伏、工点分散、桥墩普遍较高的特点,以浙江西部某典型山区高速为例,介绍了预制装配桥梁关键技术及应用,并就其总体方案进行阐述。重点研究下部结构选型及节段合理划分,对连接形式进行方案比选,提出了一站式架桥机的施工方案,同步实现了上下部结构的机械化安装,研究结果和实践对于探索并加大预制装配桥梁在山区公路上的应用具有重要意义。